ASH 2019 | KRd demonstrates deep and sustained reponses in NDMM
Ola Landgren
• 7 Dec 2019
Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a pooled analysis performed on data from four single-arm phase I and phase II studies (NCT01816971, NCT02405364, NCT01029054, NCT01402284) of carfilzomib, lenalidomide and dexamethasone (KRd) in newly diagnosed multiple myeloma (MM). This demonstrated deep and sustained responses with KRd in both the transplant and non-transplant settings. The promising results presented here should be evaluated against standard of care regimens.This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
